---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009543"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:08:50.451951+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx board director Lars Ekman to retire after 2023 annual meeting

## Summary
- Lars Ekman, M.D., Ph.D. will retire from the Board effective immediately after the 2023 Annual Meeting on June 7, 2023.
- Retirement is for personal reasons and not related to any disagreement with the Company or management.
- No replacement director has been announced as of the filing date.

## SEC filing metadata
- accession: 0000950170-23-009543
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017023009543/0000950170-23-009543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017023009543/rare-20230320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009543
- JSON: https://secwatch.observer/filing/0000950170-23-009543.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009543.txt

## Key facts
- Executive change
  Lars Ekman retired as Director at Ultragenyx Pharmaceutical Inc..
  - Action: retired
  - Role: Director
  source text: On March 20, 2023, Lars Ekman, M.D., Ph.D. notified Ultragenyx Pharmaceutical Inc. (the “ Company ”) of his decision to retire from the Board of Directors of the Company (the “ Board ”), effective immediately after the Company’s 2023 Annual Meeting of Stockholders, currently scheduled for June 7, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023009543/0000950170-23-009543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.